Longeveron Inc
LGVN
Company Profile
Business description
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty.
Contact
1951 NW 7th Avenue
Suite 520
MiamiFL33136
USAT: +1 305 909-0840
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Oracle’s cloud database business is riding the AI wave.
stocks
Is there a long-term buying opportunity in luxury stocks?
Our analysts think the recent wobble in revenue growth is cyclical, not structural.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.80 | 14.90 | 0.16% |
| CAC 40 | 7,872.02 | 41.91 | 0.54% |
| DAX 40 | 23,611.33 | 84.28 | 0.36% |
| Dow JONES (US) | 46,413.28 | 31.74 | 0.07% |
| FTSE 100 | 9,223.32 | 3.36 | -0.04% |
| HKSE | 26,159.12 | 185.02 | -0.70% |
| NASDAQ | 22,701.07 | 87.90 | -0.39% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,136.54 | 5.00 | -0.04% |
| S&P 500 | 6,678.58 | 15.17 | -0.23% |
| S&P/ASX 200 | 8,845.90 | 14.30 | 0.16% |
| SSE Composite Index | 3,821.83 | 6.74 | -0.18% |